Headline
The latest stories from AHA Today.
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a brand name biological product.
Whistleblowers who file a lawsuit within three years of reporting an alleged fraud to a responsible government official may have up to 10 years after the alleged fraud occurred to file a lawsuit.
The House of Representatives yesterday voted 230-183 to pass AHA-supported legislation (H.R. 986) that would rescind the administration’s latest guidance for states seeking a Section 1332 waiver of certain Affordable Care Act requirements.
The Food and Drug Administration yesterday published draft guidance to promote clinical studies to increase drug safety information for pregnant and nursing women and their providers.
The White House yesterday released a strategy to guide the federal government in protecting the nation from infectious disease threats by working with other nations and stakeholders.
President Trump today released guiding principles for addressing surprise medical bills.
The House Energy and Commerce Subcommittee on Health today held a hearing on lowering prescription drugs prices, which focused on the drug supply chain.
At an AHA executive forum today in Atlanta, hospital and health system leaders shared insights and explored opportunities and challenges for driving innovation and value through collaboration with providers, payers, employers and community partners.
The AHA today responded to a RAND Corporation study that found that certain prices paid to hospitals by private health plans are high relative to Medicare and vary widely.
The Department of Justice this week issued formal guidance on how it awards credit to defendants who cooperate during a False Claims Act investigation.